Double-blind, Randomized Placebo Controlled Study of the Relative Safety and Efficacy of Collagenase Therapy in the Treatment of Residual-type Dupuytren's Disease.
Phase of Trial: Phase III
Latest Information Update: 23 Jun 2015
Price : $35 *
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Dupuytren's contracture
- Focus Registrational; Therapeutic Use
- 08 May 2014 According to a Biospecifics Technologies Corporation media release, the supplement biologics license application (sBLA) for potential label expansion of Xiaflex is under FDA review with a PDUFA date of October 20, 2014.
- 22 Oct 2013 New trial record